Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression - PubMed (original) (raw)

Affiliations

PMID: 18202756

Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression

Silvia Niesporek et al. Int J Oncol. 2008 Feb.

Abstract

The human ELAV-like protein HuR is involved in the stabilization of the mRNAs of a group of genes implicated in the regulation of cellular growth, angiogenesis and rapid inflammatory response. HuR is a nuclear shuttling protein, translocating bound mRNAs from the nucleus to the cytoplasm. We have previously observed an increased expression of cyclooxygenase-2 (COX-2) in prostate cancer while cell culture studies have shown that HuR stabilizes the mRNA of COX-2. Based on these mechanistic data, we aimed to investigate the role of HuR in prostate cancer by a tissue-based analysis combined with functional evaluation using a cell culture approach. Investigating 104 primary prostate carcinomas by immunohistochemistry, we found HuR expression to be shifted from a nuclear staining in normal prostate glands to a cytoplasmic staining in carcinoma tissue (p<0.0001). Cytoplasmic HuR expression was significantly correlated with COX-2 expression (p=0.005). Loss of nuclear HuR expression was an indicator of earlier PSA-relapse both in univariate (p=0.04) and multivariate survival analysis (p=0.04). HuR inhibition by Leptomycin B reduced the inducibility of COX-2 in PC-3 prostate cancer cells. We found that the subcellular localization of HuR is deregulated in a subset of prostate carcinomas, and that this deregulation is linked to an altered expression of the tumorigenic COX-2 protein as well as to an adverse patient prognosis. Our results point to a potential prognostic role of HuR expression in prostate cancer diagnostics and propose HuR as a future therapeutic target in prostate cancer therapy.

PubMed Disclaimer

Cited by

Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-Regulation.
Al-Ahmadi W, Al-Ghamdi M, Al-Haj L, Al-Saif M, Khabar KS. Al-Ahmadi W, et al. Nucleic Acids Res. 2009 Jun;37(11):3612-24. doi: 10.1093/nar/gkp223. Epub 2009 Apr 9. Nucleic Acids Res. 2009. PMID: 19359363 Free PMC article.
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
Jimbo M, Blanco FF, Huang YH, Telonis AG, Screnci BA, Cosma GL, Alexeev V, Gonye GE, Yeo CJ, Sawicki JA, Winter JM, Brody JR. Jimbo M, et al. Oncotarget. 2015 Sep 29;6(29):27312-31. doi: 10.18632/oncotarget.4743. Oncotarget. 2015. PMID: 26314962 Free PMC article.
Multiple functions of HuR in urinary tumors.
Zhang F, Cai Z, Lv H, Li W, Liang M, Wei X, Zhou F. Zhang F, et al. J Cancer Res Clin Oncol. 2019 Jan;145(1):11-18. doi: 10.1007/s00432-018-2778-2. Epub 2018 Oct 28. J Cancer Res Clin Oncol. 2019. PMID: 30370480 Review.
Inhibition of Caspase-2 Translation by the mRNA Binding Protein HuR: A Novel Path of Therapy Resistance in Colon Carcinoma Cells?
Eberhardt W, Nasrullah U, Haeussler K. Eberhardt W, et al. Cells. 2019 Jul 30;8(8):797. doi: 10.3390/cells8080797. Cells. 2019. PMID: 31366165 Free PMC article. Review.
High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.
Braun K, Ehemann V, Wiessler M, Pipkorn R, Didinger B, Mueller G, Waldeck W. Braun K, et al. Int J Med Sci. 2009 Nov 18;6(6):338-47. doi: 10.7150/ijms.6.338. Int J Med Sci. 2009. PMID: 19946604 Free PMC article.

Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression - PubMed (original) (raw)